-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The US FDA will make a decision on Biogen's aducanumab on June 7
.
If approved, it will be the first treatment for Alzheimer's disease to be marketed in more than two decades
The US FDA will make a decision on Biogen's aducanumab on June 7
Analyst Iuri Struta said in the study that Biogen was not prepared for the patent cliffs of the three key multiple sclerosis drugs Tysabri, Tecfidera and Vumerity
.
"Uncertainty about the company's next revenue driver has weakened investor confidence
At the same time, sales data show that the company's sales are declining rapidly
.
Bojian’s annual income has fallen for the first time in decades in 2020, and has dropped sharply from US$14.
According to Struta, aducanumab is "the only real hope to avoid falling into the patent cliff
.
" The drug is designed to break down the accumulation of amyloid plaques that are thought to aggravate Alzheimer's disease
Insightia stated that, apart from these efforts, Bojian does not have enough measures to maintain sales by 2024.
Bojian CEO Michel Vounatsos aims to let Bojian's early investment and development drugs enter the market in 2024
.
Struta said, "Activist investors may question whether the management team is not performing well or following the wrong strategy
Insightia pointed out that since Vounatsos took over in 2017, Bojian has only made one acquisition, that is, the acquisition of Nightstar Therapeutics for US$800 million.
The company has brought promising drugs but has not solved recent problems
.
Insightia's possible alternative to Bojian: You can sell itself or merge with competitors
It is not the first time for Bojian that activist investors have put pressure on the company
.
More than a decade ago, billionaire investor Carl Icahn argued with the company on the same issue, claiming that the company was poorly managed and underperformed compared to its peers
Before the FDA made a decision on aducanumab, Brian Abrahams of RBC Capital Markets has warned investors to be prepared, not only for the substantial changes in Bojian’s stock, but also for other sales.
Changes in the stocks of Haimer's disease treatment companies, and even those companies that may become the targets of Bojian's acquisition, including Eisai
.
Abrahams pointed out, "The FDA's upcoming decision on aducanumab is not only critical for Bojian, but may also have repercussions in the entire biopharmaceutical field, affecting the overall sentiment in the field, regulatory flexibility and business development dynamics.
View
.
"